(MENAFN- GlobeNewsWire - Nasdaq) Key segments include Chlamydia, HIV, and molecular diagnostics, with growing trends in point-of-care and home testing. The market thrives on global initiatives for early detection and effective treatment to prevent complications. Challenges remain in stigma and affordable access, particularly in low-income regions.

Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "STD Diagnostics Market Report by Test Type, Technology, Location of Testing, End User, Countries and Company Analysis, 2025-2033" has been added to ResearchAndMarkets's offering.

The STD Diagnostics market is anticipated to grow from US$ 16.82 billion in 2024 to US$ 30.84 billion by 2033, with remarkable growth. The growth is anticipated at a compound annual growth rate (CAGR) of 6.97% during the period 2025-2033. This growth is driven by increasing awareness regarding STDs, advancements in diagnostic technology, and growing demands for speedy and precise diagnosis techniques.

Growth Drivers in the Global STD Diagnostics Market

Increasing Global Incidence of STDs

The rising incidence of sexually transmitted diseases (STDs), such as HIV, syphilis, gonorrhea, and chlamydia, is a principal growth driver of the STD diagnostics market. With over 1 million new STIs diagnosed daily globally, there is an immediate need for precise diagnostics. Increased incidence among youths, young adults, and high-risk groups signify the need for early detection and prevention. Media campaigns and public health activities promote testing, fueling demand for rapid and precise diagnostics.

Untreated infections frequently result in severe complications, driving the high demand for diagnostic products worldwide.

Advances in Diagnostic Technologies

Technological advancements are driving growth in the market for STD diagnostics. Rapid diagnosis tests (RDTs), point-of-care (POC) tests, and molecular-based methods like nucleic acid amplification tests (NAATs) have greatly enhanced precision and speed. These developments make it possible for healthcare professionals to diagnose infections faster, resulting in earlier treatment and lower transmission rates.

Self-testing kits are becoming popular, especially among the youth and privacy-aware individuals. Furthermore, automation and AI incorporation in lab diagnostics are becoming more efficient. All these improvements are not only enhancing outcomes but also increasing accessibility to testing.

In April 2023, Jiangsu Bioperfectus Technologies Co., Ltd. released news of CE marking of its brand-new Herpes Simplex Virus Type I/II Real Time PCR Kit, offering a comprehensive solution for STD early detection.

Expanding Government and NGO Initiatives

Governments and agencies like WHO and UNAIDS are aggressively launching STD transmission control programs, building powerful momentum for the diagnostics market. Efforts in encouraging early testing, awareness drives, and discounted diagnostic services are making diagnostics more accessible. Healthcare infrastructure investments and screening programs are increasing diagnostic coverage. NGO partnerships further enhance access to affordable testing.

In February 2024, Canada's government introduced the STBBI action plan 2024-2030 and unveiled $2.45 million in funding to address the rise of STBBIs.

Challenges in the Global STD Diagnostics Market
Social Stigma and Limited Awareness

Despite increasing prevalence, social stigma regarding STDs remains a significant constraint to adopting diagnostics. Many avoid testing due to fear of judgment or cultural taboos. This stigma disproportionately impacts younger groups and women in conservative cultures. Poor awareness regarding the existence of confidential diagnostic solutions also contributes. Therefore, underdiagnosis and treatment of infections dilute global control measures.

High Costs and Limited Access in Low-Income Regions

Accessibility and affordability in low- and middle-income countries remain a challenge, where STDs are most prevalent. Sophisticated tests like NAATs are highly accurate but typically too costly, requiring laboratory facilities that may not exist in resource-poor settings. Rapid tests alleviate somewhat, but their sensitivity could be lower. Healthcare disparities restrict access, especially in rural communities. Removing cost hurdles and ensuring access are critical to enhancing market development and global public health benefits.

Key Attributes

Report Attribute	Details
No. of Pages	200
Forecast Period	2024-2033
Estimated Market Value (USD) in 2024	$16.82 Billion
Forecasted Market Value (USD) by 2033	$30.84 Billion
Compound Annual Growth Rate	6.9%
Regions Covered	Global

Key Topics Covered

1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global STD Diagnostics Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 By Test Type
6.2 By Technology
6.3 By Location of Testing
6.4 By End User
6.5 By Countries

7. Test Type
7.1 Chlamydia Testing
7.2 Gonorrhea Testing
7.3 Syphilis Testing
7.4 HPV Testing
7.5 HSV Testing
7.6 HIV Testing
7.7 Trichomonas Testing
7.8 Mycoplasma Genitalium Testing
7.9 Chancroid Testing

8. Technology
8.1 Immunoassay-based Methods
8.2 Molecular Diagnostics
8.3 Next-Generation Sequencing
8.4 Biosensor / Microfluidics & Other Emerging Platforms

9. Location of Testing
9.1 Central & Hospital Laboratories
9.2 Rapid Point-of-Care Platforms
9.3 Over-the-Counter / Home Self-Testing

10. End User
10.1 Hospitals & Clinics
10.2 Diagnostic Laboratories
10.3 Home Care / OTC

11. Countries
11.1 North America
11.2 Europe
11.3 Asia Pacific
11.4 Latin America
11.5 Middle East & Africa

12. Value Chain Analysis

13. Porter's Five Forces Analysis
13.1 Bargaining Power of Buyers
13.2 Bargaining Power of Suppliers
13.3 Degree of Competition
13.4 Threat of New Entrants
13.5 Threat of Substitutes

14. SWOT Analysis
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threats

15. Pricing Benchmark Analysis

16. Key Players Analysis
16.1 Abbott Laboratories
16.2 F. Hoffmann-La Roche AG
16.3 Hologic Inc.
16.4 Becton Dickinson and Company
16.5 Danaher Corporation (Cepheid)
16.6 Siemens Healthineers AG
16.7 bioMerieux SA
16.8 Thermo Fisher Scientific Inc.
16.9 Qiagen N.V.
16.10 Bio-Rad Laboratories Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• STD Diagnostics Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06112025004107003653ID1110306313